AMLX — Amylyx Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$37.46
-$0.69 (-1.81%)
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on NASDAQ. It is led by Joshua B. Cohen, based in 43 Thorndike Street, Cambridge, MA, United States, 02141, with about 123 employees. Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest reported AMLX revenue for 2025-09-30 was $0. Net income was -$111.7M. AMLX currently screens at market cap $561.6M.
Use this AMLX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AMLX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AMLX SEC filings page. Lician reads the product cache first so this HTML stays unique to Amylyx Pharmaceuticals Inc even when a live quote feed is slow.
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Key Statistics
Market Cap
$561.59M
Volume
2.14M
Previous Close
$38.15
Day Range
$36.84 – $38.88
EPS
-$4.43
Revenue
$87.37M
Net Income
-$301.74M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-77.1%
Profit Margin
-345.4%
Employees
123
AMLX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $87.37M | $380.79M | $22.23M | $285.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$301.74M | $49.27M | -$198.38M | -$87.93M |
| EPS (Diluted) | -$4.43 | $0.70 | -$3.39 | -$13.35 |
Total Assets
$193.63M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$77.39M
Operating Cash Flow
-$167.65M
Free Cash Flow
$0.00
Amylyx Pharmaceuticals Inc Company Information
- Co-Founder, Co-CEO & Director
- Joshua B. Cohen
- Headquarters
- 43 Thorndike Street, Cambridge, MA, United States, 02141
- Website
- amylyx.com
- Phone
- 617 682 0917
- IPO / Founded
- 2022-01-07
- Sector
- Healthcare
- Industry
- Biotechnology